Chronic kidney disease (CKD) poses an increasing burden on global health, however there are few interventions available to manage the condition. It has been hypothesised that metformin, a commonly prescribed oral antidiabetic drug, may potentially be able to slow the progression of CKD.1 Metformin is the first line treatment for patients with type 2 diabetes mellitus (T2DM) due to its beneficial effects on blood glucose control and its tolerability.1 It primarily imparts its therapeutic actions through activation of adenosine monophosphate (AMP)-activated protein kinase, which subsequently inactivates the molecular target of rapamycin and its postulated downstream fibrogenic effects on the kidney.
No takes yet. Share an insight, caveat, or question.
Stanley et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: